MODERN APPROACH TO MOLECULAR CHARACTERIZATION OF PROSTATE TUMORS
Abstract
The aim of the study was the development of a cell biosensor system based on the fact that AR activator stimuli lead to redistribution of AR from cytoplasm to the nucleus. These changes could be measured and used for the diagnostics and personalized treatment of prostate cancer patient. The stably transfected cell lines with fluorescently tagged AR were generated. For the stable cell expression the non AR expressing HeLa cell line was used. The constructs of chimeric fluorescent proteins wild type AR or mutant ART877A were used for the transfection. The changes of the CFP-AR-YFP and CFP-ART877A-YFP proteins in the nucleus of HeLa cells under different concentrations steroids treatment was investigated. Moreover, the quantity of activated receptor in the nucleus was carried.
About the Authors
E. P. Khvostova
Institute of Molecular Biology and Biophysics, Siberian Branch of Russian Academy of Medical Sciences; Novosibirsk State University
Russian Federation
Russian Federation
V. O. Pustylnyak
Institute of Molecular Biology and Biophysics, Siberian Branch of Russian Academy of Medical Sciences; Novosibirsk State University
Russian Federation
Russian Federation
A. I. Korbut
Novosibirsk State University
Russian Federation
Russian Federation
A. A. Otpuschennikov
Central Clinical Hospital Siberian Branch of Russian Academy of Sciences
Russian Federation
Russian Federation
L. F. Gulyaeva
Institute of Molecular Biology and Biophysics, Siberian Branch of Russian Academy of Medical Sciences; Novosibirsk State University
Russian Federation
Russian Federation
I. N. Krylova
Novosibirsk State University
Russian Federation
Russian Federation
References
1. Чисов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской Федерации // Экспериментальная и клиническая урология. — 2011. — № 2 — 3. — C. 6 — 7.
2. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines / H. Nakauchi [et al.] // J. Histochem. Cytochem. - 2007. - Vol. 55. - P. 535-544.
3. Ahmad N., Kumar R. Steroid hormone receptors in cancer development: a target for cancer therapeutics // Cancer letters. - 2011. - Vol. 300. - P. 1-9.
4. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease / M.J. Donovan [et al.] // BJU international. - 2010. - Vol. 105. - P. 462-467.
5. Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems / N. Kaku [et al.] // Endocrinol. - 2008. - Vol. 149. - P. 3960-3969.
6. Day R.N., Schaufele F. Fluorescent protein tools for studying protein dynamics in living cells: a review // J. Biomedical Optic. - 2008. - Vol. 13. -P. 031202.
7. De S., Macara I.G., Lannigan, D.A. Novel biosensors for the detection of estrogen receptor ligands // J. Steroid Biochem. Mol. Biol. - 2005. -Vol. 96. - P. 235-244.
8. Development of androgen- and estrogen-responsive bioassays, members of a panel of human cell line-based highly selective steroid-responsive bioassays / E. Sonneveld [et al.] // Toxicol Sci. - 2005. - Vol. 83, № 1. - P. 136-148.
9. Dutt S.S., Gao A.C. Molecular mechanisms of castration-resistant prostate cancer progression // Fut. Oncol. - 2009. - Vol. 5. - P. 1403-1413.
10. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer // Adv. Exp. Med. Boil. - 2007. - Vol. 608. - P. 1-22.
11. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy / R. Li [et al.] // Am. J. Surg. Pathol. - 2004. -Vol. 28. - P. 928-934.
12. Imaging local estrogen production in single living cells with recombinant fluorescent indicators / F. Picazo [et al.] // Biosens. Bioelectron. - 2010. -Vol. 26. - P. 2147-2153.
13. Intracrinology of estrogens and androgens in breast carcinoma / H. Sasano [et al.] // J. Steroid Biochem. Mol. Boil. - 2008. - Vol. 108. - P. 181-185.
14. Rastelli F., Crispino S. Factors predictive of response to hormone therapy in breast cancer // Tumori. - 2008. - Vol. 94. - P. 370-383.
15. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H / D.J. Wijngaart [et al.] // J. Biol. Chem. - 2010. - Vol. 285, № 7. - P. 5097-5105.
16. Systems cell biology based on high-content screening / K.A. Giuliano [et al.] // Methods. Enzymol. - 2006. - Vol. 414. - P. 601-619.
17. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis // J. Clin. Oncol. - 2005. - Vol. 23. - P. 8253-8261.
18. Taplin M.E. Androgen receptor: role and novel therapeutic prospects in prostate cancer // Expert Rev. Anticancer Ther. - 2008. - Vol. 8. -P. 1495-1508.
19. Trafficking of nuclear receptors in living cells / G.L. Hager [et al.] // J. Steroid Biochem. Mol. Biol. - 2000. - Vol. 74. - P. 249-254.
20. Vasaitis T.S., Bruno R.D., Njar V.C. CYP17 inhibitors for prostate cancer therapy // J. Steroid Biochem. Mol. Biol. - 2011. - Vol. 125, № 1-2. -P. 23-31.
21. Visualizing the action of steroid hormone receptors in living cells / A. Griekspoor [et al.] // Nucl. Recap. Signal. - 2007. - Vol. 5. - P. e003.
Review
For citations:
Khvostova E.P., Pustylnyak V.O., Korbut A.I., Otpuschennikov A.A., Gulyaeva L.F., Krylova I.N. MODERN APPROACH TO MOLECULAR CHARACTERIZATION OF PROSTATE TUMORS. Acta Biomedica Scientifica. 2012;(3(1)):83-88. (In Russ.)
Views:
367
Email this article 
